Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 4, 2009, Pages 463-467

  Milczek, Tomasz ^a   Klasa Mazurkiewicz, Dagmara ^a   Emerich, Janusz ^a   Kobierski, Juliusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

chemotherapy; intraperitoneal; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PLATINUM; SODIUM THIOSULFATE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; INFECTION; INTESTINE PERFORATION; KIDNEY DISEASE; LAPAROTOMY; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; OVARY CANCER; PATIENT REFERRAL; POLAND; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TIME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 64849094912     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340902777525     Document Type: Article

References (18)

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351: 2519-29.
2. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annal Oncol. 2005;16 Suppl 8:7-12.
3. Kawanagh JJ, Pecorelli S, BenedetJL. Cancer of the ovary. In: Benedet JL, Hacker NF, Ngan HYS, editors. Staging classification and clinical practice guidelines of gynaecologic cancers by FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee, 2nd edn. Santiago, Chile: Ushers Print & Design, 2003. pp. 92-118.
4. Hofstra LS, de Vries EG, Mulder NH, Willemse PH. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev. 2000;26:133-43.
5. Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, et al. Long-term survival of advanced refractory ovarian carcinoma patients treated with small volume disease treated with intraperitoneal chemo-therapy. J Clin Oncol. 1987;5:1607-12.
6. Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarin cancer. J Clin Oncol. 1992;10: 1479-84.
7. de Jong RS, Willemse PH, Boonstra H, de Vries EG, van der Graaf WT, Sleijfer DT, et al. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second line treatment in patients with small volume residual disease. Eur J Cancer. 1995;31:709-13.
8. Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, et al. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol. 1989;7:1327-32.
9. Braly S. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer. A phase II Gynecologic Oncology Group trial. Gynecol Oncol. 1995;56:164-8.
10. Piver MS, Recio FO, Baker TR, Driscoll D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer. 1994;73: 1693-8.
11. Markman M, Reichman B, Hakes T, Barakat R, Curtin J, Rubin S, et al. Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. J Cancer Res Clin Oncol. 1992;118:235-7.
12. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, et al. Responses to second line cisplatin based intraperitoneal chemotherapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9: 1801-5.
13. Recio FO, Piver MS, Hempling RE, Driscoll DL. Five year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol. 1998;68:267-73.
14. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003; 90:637-43.
15. Vermorken JB. The role of intraperitoneal chemotherapy in epithelial ovarian cancer. Int J Gynecol Cancer. 2000; 10(Suppl 1):26-32.
16. Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol. 2002;20:694-8.
17. Gadducci A, Conte PF Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int J Gynecol Cancer. 2008;18:943-53.
18. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.